US5932540A
(en)
|
1994-03-08 |
1999-08-03 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US6608182B1
(en)
*
|
1994-03-08 |
2003-08-19 |
Human Genome Sciences, Inc. |
Human vascular endothelial growth factor 2
|
US6040157A
(en)
*
|
1994-03-08 |
2000-03-21 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US6734285B2
(en)
*
|
1994-03-08 |
2004-05-11 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2 proteins and compositions
|
DE69434538T2
(de)
|
1994-03-08 |
2006-08-10 |
Human Genome Sciences, Inc. |
Vaskulärer endothelialer Wachstumsfaktor 2
|
US7153827B1
(en)
*
|
1994-03-08 |
2006-12-26 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2 and methods of use
|
US7109308B1
(en)
|
1994-03-08 |
2006-09-19 |
Human Genome Sciences, Inc. |
Antibodies to human vascular endothelial growth factor 2
|
US7186688B1
(en)
|
1994-03-08 |
2007-03-06 |
Human Genome Sciences, Inc. |
Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
|
US5928939A
(en)
*
|
1995-03-01 |
1999-07-27 |
Ludwig Institute For Cancer Research |
Vascular endothelial growth factor-b and dna coding therefor
|
US7160991B1
(en)
|
1995-03-02 |
2007-01-09 |
Ludwig Institute For Cancer Research |
Vascular endothelial growth factor polypeptides
|
NZ301611A
(en)
*
|
1995-03-02 |
2000-02-28 |
Amrad Operations Pty Ltd |
a peptide having vascular endothelial growth factor like properties, nucleic acid molecule encoding it and its use
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
WO1996039421A1
(en)
*
|
1995-06-06 |
1996-12-12 |
Human Genome Sciences, Inc. |
Human vascular endothelial growth factor 3
|
US7423125B2
(en)
|
1995-08-01 |
2008-09-09 |
Vegenics Limited |
Antibodies to VEGF-C
|
PT848755E
(pt)
|
1995-09-08 |
2003-12-31 |
Genentech Inc |
Proteina relacionada com o vegf
|
ATE459715T1
(de)
|
1995-09-29 |
2010-03-15 |
Univ Siena |
Regulierte gene und ihre verwendungen
|
AU1116297A
(en)
|
1995-11-08 |
1997-05-29 |
Immunex Corporation |
Flk-1 binding protein
|
US6994989B1
(en)
|
1995-11-08 |
2006-02-07 |
Immunex Corp. |
FLK-1 binding proteins
|
WO1997033904A1
(en)
|
1996-03-12 |
1997-09-18 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US6713061B1
(en)
|
1996-03-12 |
2004-03-30 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US7357927B2
(en)
|
1996-03-12 |
2008-04-15 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
DK2107109T3
(da)
|
1996-08-23 |
2012-09-24 |
Vegenics Pty Ltd |
Rekombinant vaskulær endotelcelle-vækstfaktor D (VEGF-D)
|
WO1998024811A2
(en)
*
|
1996-12-06 |
1998-06-11 |
Zymogenetics, Inc. |
Vascular endothelial growth factor
|
EP0960334A1
(de)
*
|
1996-12-20 |
1999-12-01 |
Ludwig Institute For Cancer Research |
Vegf-b/rezeptorkomplex und anwendung
|
AU6691098A
(en)
|
1997-03-07 |
1998-09-22 |
Wistar Institute Of Anatomy & Biology, The |
Method and compositions for healing tissue defects and inducing hypervascularityin mammalian tissue
|
JP2001524828A
(ja)
*
|
1997-04-25 |
2001-12-04 |
コラテラル・セラピューティクス |
切断型vegf関連蛋白質
|
US6281175B1
(en)
|
1997-09-23 |
2001-08-28 |
Scimed Life Systems, Inc. |
Medical emulsion for lubrication and delivery of drugs
|
AU767662B2
(en)
|
1998-02-06 |
2003-11-20 |
Collateral Therapeutics, Inc. |
Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF
|
DE19813774A1
(de)
*
|
1998-03-27 |
1999-09-30 |
Max Planck Gesellschaft |
Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
|
US20030118567A1
(en)
*
|
1999-03-26 |
2003-06-26 |
Stewart Duncan John |
Cell-based therapy for the pulmonary system
|
WO2000027879A1
(en)
|
1998-11-10 |
2000-05-18 |
Ludwig Institute For Cancer Research |
Platelet-derived growth factor d, dna coding therefor, and uses thereof
|
US6783953B1
(en)
|
1998-12-22 |
2004-08-31 |
Janssen Pharmaceutica N.V. |
Vascular endothelial growth factor-X
|
AU3693000A
(en)
*
|
1999-01-29 |
2000-08-18 |
Licentia Ltd |
Platelet-derived growth factor/vascular endothelial growth factor-like growth factor h, and uses thereof
|
US7223724B1
(en)
|
1999-02-08 |
2007-05-29 |
Human Genome Sciences, Inc. |
Use of vascular endothelial growth factor to treat photoreceptor cells
|
WO2000050620A2
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
WO2000052462A1
(en)
*
|
1999-03-03 |
2000-09-08 |
Ludwig Institute For Cancer Research |
Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities
|
AU4662400A
(en)
*
|
1999-04-26 |
2000-11-10 |
Helsinki University Licensing Ltd |
Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
|
WO2000075329A1
(en)
*
|
1999-06-07 |
2000-12-14 |
Edwards Lifesciences Corporation |
Targeted angiogenesis
|
US8188043B2
(en)
*
|
1999-07-28 |
2012-05-29 |
The Board Of Trustees Of The Leland Stanford Jr. University |
Nicotine in therapeutic angiogenesis and vasculogenesis
|
BR0012793A
(pt)
*
|
1999-07-28 |
2002-04-30 |
Univ Leland Stanford Junior |
Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina
|
DE60136334D1
(en)
*
|
2000-02-02 |
2008-12-11 |
Us Health |
Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
|
AUPQ568100A0
(en)
*
|
2000-02-16 |
2000-03-09 |
Amrad Operations Pty. Limited |
A method for producing recombinant molecules
|
ATE377081T1
(de)
*
|
2000-02-25 |
2007-11-15 |
Ludwig Inst Cancer Res |
Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
|
AUPQ592100A0
(en)
*
|
2000-02-29 |
2000-03-23 |
Council Of The Queensland Institute Of Medical Research, The |
A method of treatment and prophylaxis
|
US20030104977A1
(en)
*
|
2000-03-31 |
2003-06-05 |
Ugo Ripamonti |
Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
|
AU2001259063A1
(en)
|
2000-04-12 |
2001-10-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
CN1441849A
(zh)
*
|
2000-05-17 |
2003-09-10 |
路德维格癌症研究所 |
检测肿瘤细胞的存在及筛选抗肿瘤剂的方法
|
CA2417508A1
(en)
*
|
2000-07-26 |
2002-01-31 |
Ludwig Institute For Cancer Research |
Glycosylated vegf-b and method for increasing the amount of soluble vegf-b
|
US7273751B2
(en)
*
|
2000-08-04 |
2007-09-25 |
Human Genome Science, Inc. |
Vascular endothelial growth factor-2
|
US20020151489A1
(en)
*
|
2000-10-02 |
2002-10-17 |
St. Elizabeth's Medical Center Of Boston, Inc. |
Use of lymphangiogenic agents to treat lymphatic disorders
|
US6793918B2
(en)
*
|
2000-11-01 |
2004-09-21 |
Ludwig Institute For Cancer Research |
In vivo stimulation of angiogenic activity
|
US7067317B2
(en)
*
|
2000-12-07 |
2006-06-27 |
Sangamo Biosciences, Inc. |
Regulation of angiogenesis with zinc finger proteins
|
AU2884102A
(en)
*
|
2000-12-07 |
2002-06-18 |
Sangamo Biosciences Inc |
Regulation of angiogenesis with zinc finger proteins
|
US7611711B2
(en)
|
2001-01-17 |
2009-11-03 |
Vegenics Limited |
VEGFR-3 inhibitor materials and methods
|
US20070111944A1
(en)
*
|
2001-02-16 |
2007-05-17 |
Scrofani Sergio D B |
Purification of vascular endothelial growth factor-B
|
US20070050857A1
(en)
*
|
2001-02-28 |
2007-03-01 |
Hayward Nick K |
Method of treatment and prophylaxis
|
WO2002081639A2
(en)
*
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
WO2002083849A2
(en)
*
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US20050232921A1
(en)
*
|
2001-04-13 |
2005-10-20 |
Rosen Craig A |
Vascular endothelial growth factor 2
|
US20030170786A1
(en)
*
|
2001-04-13 |
2003-09-11 |
Rosen Craig A. |
Vascular endothelial growth factor 2
|
US7402312B2
(en)
*
|
2001-04-13 |
2008-07-22 |
Human Genome Sciences, Inc. |
Antibodies to vascular endothelial growth factor 2 (VEGF-2)
|
DK1385864T3
(da)
|
2001-04-13 |
2010-08-16 |
Human Genome Sciences Inc |
Anti-VEGF-2-antistoffer
|
ATE446514T1
(de)
*
|
2001-04-24 |
2009-11-15 |
Vlaams Interuniv Inst Biotech |
VERWENDUNG VON ßHYPOXIA INDUCIBLE FACTOR 2ALPHAß ZUR BEHANDLUNG VON ßNEONATAL RESPIRATORY DISTRESS SYNDROMEß
|
WO2003000009A2
(en)
*
|
2001-06-20 |
2003-01-03 |
Ludwig Institute For Cancer Research |
Stimulation of vascularization with vegf-b
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
DK1399484T3
(da)
*
|
2001-06-28 |
2010-11-08 |
Domantis Ltd |
Dobbelt-specifik ligand og anvendelse af denne
|
JP2005500045A
(ja)
*
|
2001-07-12 |
2005-01-06 |
ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ |
リンパ管内皮細胞材料および方法
|
WO2003018752A2
(en)
|
2001-08-23 |
2003-03-06 |
The Wistar Institute Of Anatomy And Biology |
An organotypic intestinal culture and methods of use thereof
|
US20030113324A1
(en)
|
2001-10-01 |
2003-06-19 |
Kari Alitalo |
Neuropilin/VEGF-C/VEGFR-3 materials and methods
|
US20040214766A1
(en)
*
|
2001-10-01 |
2004-10-28 |
Kari Alitalo |
VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
|
EP1463751B1
(de)
|
2001-12-21 |
2013-05-22 |
Human Genome Sciences, Inc. |
Albuminfusionsproteine
|
US20030221931A1
(en)
*
|
2002-02-28 |
2003-12-04 |
Steve Marsh |
Sliding device
|
CA2429483A1
(en)
*
|
2002-05-17 |
2003-11-17 |
Amrad Operations Pty Ltd. |
Immunointeractive molecules
|
EP1514114A4
(de)
*
|
2002-06-05 |
2007-03-21 |
Sopherion Therapeutics Inc |
Verfahren zum screening von liganden unter verwendung von eukaryontischem zell-display
|
EP1912069A3
(de)
|
2002-06-05 |
2008-07-09 |
Sopherion Therapeutics, Inc. |
Verfahren für Schirmliganden mit eukaryotischer Zellenanzeige
|
US20030232439A1
(en)
*
|
2002-06-17 |
2003-12-18 |
Isis Pharmaceuticals Inc. |
Antisense modulation of VEGF-B expression
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
DE60305919T2
(de)
*
|
2002-06-28 |
2007-01-18 |
Domantis Limited, Cambridge |
Dual-specifische liganden mit erhöhter halbwertszeit
|
AU2003252039A1
(en)
|
2002-07-23 |
2004-02-09 |
Vegenics Limited |
Methods and compositions for activating or inhibiting vegf-d and vegf-c
|
US7470538B2
(en)
*
|
2002-12-05 |
2008-12-30 |
Case Western Reserve University |
Cell-based therapies for ischemia
|
WO2004052177A2
(en)
*
|
2002-12-05 |
2004-06-24 |
Case Western Reserve University |
Cell-based therapies for ischemia
|
CA2511910A1
(en)
*
|
2002-12-27 |
2004-07-15 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
WO2004070018A2
(en)
*
|
2003-02-04 |
2004-08-19 |
Ludwig Institute For Cancer Research |
Vegf-b and pdgf modulation of stem cells
|
DK1660057T3
(da)
|
2003-08-27 |
2012-08-20 |
Ophthotech Corp |
Kombinationsterapi til behandling af neovaskulære øjenlidelser
|
EP1560025A3
(de)
*
|
2003-10-03 |
2011-09-07 |
F. Hoffmann-La Roche AG |
Marker spezifisch für Diabetes
|
US20060003008A1
(en)
|
2003-12-30 |
2006-01-05 |
Gibson John W |
Polymeric devices for controlled release of active agents
|
US20050214280A1
(en)
*
|
2004-03-02 |
2005-09-29 |
Ludwig Institute For Cancer Research |
Method for inhibiting tumor formation and growth
|
WO2005087812A1
(en)
*
|
2004-03-05 |
2005-09-22 |
Ludwig Institute For Cancer Research |
Multivalent antibody materials and methods for vegf/pdgf family of growth factors
|
US20060024302A1
(en)
*
|
2004-03-05 |
2006-02-02 |
Ludwig Institute For Cancer Research |
Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
|
CA2561714A1
(en)
*
|
2004-04-08 |
2005-10-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathic and neurodegenerative conditions
|
PL1781321T3
(pl)
*
|
2004-08-02 |
2014-07-31 |
Zenyth Operations Pty Ltd |
Sposób leczenia raka zawierający antagonistę VEGF-B
|
US7595149B1
(en)
|
2004-11-08 |
2009-09-29 |
University Of Kentucky Research Foundation |
Methods for cancer detection
|
JP4988606B2
(ja)
*
|
2005-02-28 |
2012-08-01 |
サンガモ バイオサイエンシズ インコーポレイテッド |
抗血管新生方法及び組成物
|
KR20080041145A
(ko)
*
|
2005-04-12 |
2008-05-09 |
인트라디그엠 코오포레이션 |
암 및 다른 신생혈관증식 질환을 치료하기 위한 RNAi치료제의 조성물 및 방법
|
US7893244B2
(en)
*
|
2005-04-12 |
2011-02-22 |
Intradigm Corporation |
Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
|
AU2006279462A1
(en)
*
|
2005-08-15 |
2007-02-22 |
Vegenics Limited |
Modified VEGF and PDGF with improved angiogenic properties
|
TW200730539A
(en)
*
|
2005-12-01 |
2007-08-16 |
Domantis Ltd |
Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
|
DK2548578T3
(da)
|
2006-05-17 |
2014-10-06 |
Ludwig Inst Cancer Res |
Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdomme
|
WO2008085229A2
(en)
*
|
2006-11-15 |
2008-07-17 |
Arteriocyte Inc. |
Cell-based therapies for treating liver disease
|
NZ580530A
(en)
*
|
2007-06-06 |
2012-04-27 |
Domantis Ltd |
Anti vegf polypeptides, antibody variable domains and antagonists
|
US7819579B2
(en)
*
|
2007-11-26 |
2010-10-26 |
Schmulenson Harold K |
Radiation sensing device and holder
|
WO2009075565A1
(en)
*
|
2007-12-12 |
2009-06-18 |
Erasmus University Medical Center Rotterdam |
Methods for controlling vasculogenesis
|
KR101642846B1
(ko)
|
2007-12-26 |
2016-07-26 |
백시넥스 인코포레이티드 |
항-c35 항체 병용 치료 및 방법
|
EP2271365A4
(de)
*
|
2008-04-09 |
2011-10-26 |
Ludwig Inst Cancer Res |
Regulierung von fettsäuretransportern
|
IL205774A0
(en)
*
|
2010-05-13 |
2010-12-30 |
Muhammad Abdulrazik |
Novel compounds for the treatment of glaucoma and ocular hypertension
|
KR101335203B1
(ko)
*
|
2010-03-26 |
2013-11-29 |
숙명여자대학교산학협력단 |
혈관신생촉진용 펩타이드 및 이의 용도
|
WO2011154308A1
(en)
|
2010-06-08 |
2011-12-15 |
Proyecto De Biomedicina Cima, S.L. |
New compositions and cell therapy methods for the treatment of cirrhosis
|
RU2477529C2
(ru)
*
|
2011-04-28 |
2013-03-10 |
Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" |
Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к эндотелиальной синтазе оксида азота человека
|
KR20230152151A
(ko)
|
2013-07-12 |
2023-11-02 |
이베릭 바이오, 인크. |
안과적 질환을 치료하거나 예방하기 위한 방법
|
JP6553618B2
(ja)
*
|
2013-12-18 |
2019-07-31 |
シーエスエル リミティド |
創傷を治療する方法
|
CN107537026A
(zh)
*
|
2017-08-31 |
2018-01-05 |
中山大学中山眼科中心 |
Vegf‑b的应用
|
CN107661492A
(zh)
*
|
2017-08-31 |
2018-02-06 |
中山大学中山眼科中心 |
Vegf‑b的新用途
|
US10745454B2
(en)
*
|
2018-01-31 |
2020-08-18 |
Seyed Mohsen Asghari |
Method of synthesizing antagonist peptides for cell growth
|
CN109337931A
(zh)
*
|
2018-11-02 |
2019-02-15 |
东北师范大学 |
Vegfb基因的应用及vegfb肿瘤诱导和肿瘤抑制动物模型的构建方法
|
CN110777146A
(zh)
*
|
2019-11-28 |
2020-02-11 |
南通大学 |
一种pdgfb启动子活性报告质粒的构建方法
|